Discovery of WNT9B Gene Mutation Significantly Increases Prostate Cancer Risk
/0 Comments/in Observational/by MaxEcDNA and Prostate Cancer: A New Frontier in Understanding Resistance
/0 Comments/in Preclinical Research/by MaxHydrogel Breakthrough May Improve Cancer Vaccines
/0 Comments/in Immunotherapy, Not PCa related, Preclinical Research/by MaxCaRe Trial Expands to Include Veterans
/0 Comments/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxNewsletter 4/2025
/0 Comments/in Newsletter/by MaxLAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hi, fellow fighters! I’m back on track. This past week was packed with new clinical trial information. I want to highlight the ever-increasing role of AI in drug discovery—we are truly living in a transformative time. As usual, we also have a […]
Phase 1 Trial: Pocenbrodib, A New (AI Based) Approach for mCRPC
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1/2 Study: Evofosfamide With Immune Checkpoint Inhibitors for Advanced Cancers
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ASCO 2025 ATM bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy castration-resistant prostate cancer CDK12 clinical trial clinical trials crispr CYP11A1 inhibitor darolutamide drug repurposing drug resistance enzalutamide HRR immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA nanotechnology olaparib oncolytic virus personalized medicine prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy theranostics
Latest Posts
- Newsletter 23/2025 June 8, 2025
- Protein Design Leaps Forward Thanks to AI June 5, 2025
- Phase 1 Trial of XL309: USP1 Inhibitor Targeting DNA Repair in Solid Tumors June 5, 2025
- UPDATE About ACE-232: Phase 1 Trial of a Novel CYP11A1 Inhibitor for mCRPC June 5, 2025